Stage ivb prostate cancer ajcc v8 Trials in Los Angeles, United States
Conditions / Stage ivb prostate cancer ajcc v8 / Los Angeles, United States
Stage ivb prostate cancer ajcc v8 is a medical condition with active clinical research programs worldwide.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05053152 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | RECRUITING | PHASE2 |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | RECRUITING | — |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | RECRUITING | PHASE3 |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | RECRUITING | — |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | RECRUITING | — |
| NCT03678025 | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | RECRUITING | PHASE3 |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | RECRUITING | — |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | COMPLETED | PHASE2 |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | RECRUITING | — |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | RECRUITING | — |